The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Marketwire

ProMetic to Report Its Second Quarter 2013 Highlights and Financial Results and Hold Conference Call / Webcast

Monday, August 12, 2013

ProMetic to Report Its Second Quarter 2013 Highlights and Financial Results and Hold Conference Call / Webcast

11:12 EDT Monday, August 12, 2013

LAVAL, QUEBEC--(Marketwired - Aug. 12, 2013) - ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF) ("ProMetic" or the "Corporation") today announced that it will report its financial results for the second quarter ended June 30, 2013 on Wednesday August 14, 2013 after market trading hours.

ProMetic will host a conference call at 11:00am (EDT) on Thursday, August 15, 2013. The telephone numbers to access the conference call are (416) 981-9020 (International) and 1-800-756-3565 (North America Toll-Free). A live audio webcast of the conference call will be available via http://www.gowebcasting.com/4787.

An audio replay of the call will be available for a period of seven days as of Thursday August 15, 2013, at 1:00pm (EDT). The numbers to access the audio replay are (416) 626-4100 (international) and 1 (800) 558-5253 (North America Toll Free) using access code: 21670523.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order tto develop best-in-class therapeutics. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe and Asia.

FOR FURTHER INFORMATION PLEASE CONTACT:

Contact Information:
Pierre Laurin
President and CEO
ProMetic Life Sciences Inc
p.laurin@prometic.com
450.781.0115


Frederic Dumais
Director, Communications & Investor Relations
ProMetic Life Sciences Inc.
f.dumais@prometic.com
450-781-0115

Products
  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

GlobeLink.ca

Your number one partner for reaching Canada's Influential Achievers. learn more

The Globe at your Workplace
Our Company
Customer Service
Globe Recognition
Mobile Apps
NEWS APP
INVESTING APP
Other Sections